TG Therapeutics,
Inc.
June 9,
2017
Securities and
Exchange Commission
Department of
Corporation Finance
Washington, D.C.
20549
Attn: Ms. Ada
Sarmento
|
|
Via:
|
EDGAR
Submission
|
|
|
Re:
|
TG Therapeutics, Inc.
|
Registration
Statement on Form S-3
File No.
333-218293
Ladies and
Gentlemen:
TG Therapeutics,
Inc. (the “Company”), hereby requests that the
effective date for the Registration Statement referred to above be
accelerated so that it will be declared effective at 11:00 a.m.
(ET) on June 13, 2017 or as soon as practicable thereafter,
pursuant to Rule 461 of the Securities Act of 1933, as
amended.
The
Company acknowledges that (i) should the Commission or the staff of
the Commission, acting pursuant to delegated authority, declare the
filing effective, such declaration does not foreclose the
Commission from taking any action with respect to the filing; (ii)
the action of the Commission or the staff of the Commission, acting
pursuant to delegated authority, in declaring the filing effective,
does not relieve the Company from its full responsibility for the
adequacy and accuracy of the disclosure in the filing; and (iii)
the Company may not assert the declaration of effectiveness as a
defense in any proceeding initiated by the Commission or any person
under the federal securities laws of the United
States.
Please
contact Mark F. McElreath of Alston & Bird LLP with any
questions or comments at 212-210-9595. Thank you for your
assistance with this filing.
|
|
TG THERAPEUTICS, INC.
|
||
|
|
|
|
|
|
|
By:
|
/s/ Sean Power
|
|
|
|
|
Sean Power
|
|
|
|
|
Chief Financial Officer
|
|
|
|
cc:
|
Mark F. McElreath, Esq.
|
|
|